Ratings Sartorius Stedim Biotech

Equities

DIM

FR0013154002

Market Closed - Euronext Paris Other stock markets 11:35:15 2024-05-31 am EDT			5-day change	1st Jan Change
182.6 ^EUR	-0.27%		-5.14%	-23.74%

May. 16	Sartorius sinks again towards year low	DP
May. 16	Transcript : Sartorius Stedim Biotech S.A., Sartorius Aktiengesellschaft - Analyst/Investor Day

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.

Weaknesses

One of the major weak points of the company is its financial situation.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 51.41 times its estimated earnings per share for the ongoing year.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SARTORIUS STEDIM BIOTECH	-23.74%	19.28B	B
ABBOTT LABORATORIES	-7.16%	178B	C+
BECTON, DICKINSON AND COMPANY	-4.86%	67.04B	A
DEXCOM, INC.	-4.28%	47.24B	B-
CENCORA, INC.	+10.32%	44.62B	B-
HOYA CORPORATION	+8.14%	42.5B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+15.76%	29.99B	B
TERUMO CORPORATION	+15.53%	25.22B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-5.88%	24.14B	A-
ZIMMER BIOMET HOLDINGS, INC.	-5.38%	23.69B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes